6月3日，神经分泌生物科学（NBIX）盘中上涨5.85%，报163.81美元/股，成交额8917.82万美元。
消息面上，加拿大皇家银行资本市场近日将该公司目标价从180美元上调至183美元，维持跑赢大盘评级，并发布研报指出Crenessity（用于治疗经典先天性肾上腺皮质增生症）商业化增长仍有更多上行空间。RBC对35位内分泌科医生的调查显示，受访医生目前平均在约23%的相关患者中使用Crenessity，预计到年底将提升至37%。RBC据此将Crenessity全年销售预期从7.34亿美元上调至7.5亿美元，显著高于市场约6.5亿美元的一致预期，认为即使在更保守的增长假设下该目标仍可实现。
神经分泌生物科学是一家专注于神经科学的生物制药公司，核心产品覆盖迟发性运动障碍、亨廷顿病相关舞蹈病及先天性肾上腺皮质增生症等适应症。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.